61 related articles for article (PubMed ID: 9927055)
1. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.
Wildner O; Blaese RM; Morris JC
Cancer Res; 1999 Jan; 59(2):410-3. PubMed ID: 9927055
[TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration.
Mizuno M; Yoshida J; Colosi P; Kurtzman G
Jpn J Cancer Res; 1998 Jan; 89(1):76-80. PubMed ID: 9510479
[TBL] [Abstract][Full Text] [Related]
3. The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model.
Poorghobadi S; Hosseini SY; Sadat SM; Abdoli A; Irani S; Baesi K
Biochem Genet; 2024 Mar; ():. PubMed ID: 38436816
[TBL] [Abstract][Full Text] [Related]
4. The clinical course and management of cervical cancer with splenic metastasis: Case report and review of the literature.
Liu Q; Wang M; Gayam V; Li XL; Wang FC; Pan CQ
Clin Case Rep; 2021 Feb; 9(2):689-693. PubMed ID: 33598227
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives.
Yue NN; Xu HM; Xu J; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Yao J; Liang YJ; Li DF; Wang LS
Mol Ther Oncolytics; 2023 Sep; 30():193-215. PubMed ID: 37663132
[TBL] [Abstract][Full Text] [Related]
6. Polymeric Nanovectors Incorporated with Ganciclovir and HSV-
Sawdon AJ; Zhang J; Peng S; Alyami EM; Peng CA
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801024
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenovirus in Cancer Immunotherapy.
Peter M; Kühnel F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202717
[TBL] [Abstract][Full Text] [Related]
8. Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase.
Islam SMBU; Hong YM; Ornella MSC; Ngabire D; Jang H; Cho E; Kim EK; Hale JJJ; Kim CH; Ahn SC; Cho M; Hwang TH
Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33081279
[TBL] [Abstract][Full Text] [Related]
9. Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.
Farrera-Sal M; Fillat C; Alemany R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32340119
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.
Martin NT; Bell JC
Mol Ther; 2018 Jun; 26(6):1414-1422. PubMed ID: 29703699
[TBL] [Abstract][Full Text] [Related]
11. Trial Watch-Oncolytic viruses and cancer therapy.
Pol J; Buqué A; Aranda F; Bloy N; Cremer I; Eggermont A; Erbs P; Fucikova J; Galon J; Limacher JM; Preville X; Sautès-Fridman C; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Feb; 5(2):e1117740. PubMed ID: 27057469
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator.
Loya SM; Zhang X
Gene Ther; 2015 Mar; 22(3):237-46. PubMed ID: 25567538
[TBL] [Abstract][Full Text] [Related]
13. Classification of current anticancer immunotherapies.
Galluzzi L; Vacchelli E; Bravo-San Pedro JM; Buqué A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado JP; Agostinis P; Apte RN; Aranda F; Ayyoub M; Beckhove P; Blay JY; Bracci L; Caignard A; Castelli C; Cavallo F; Celis E; Cerundolo V; Clayton A; Colombo MP; Coussens L; Dhodapkar MV; Eggermont AM; Fearon DT; Fridman WH; Fučíková J; Gabrilovich DI; Galon J; Garg A; Ghiringhelli F; Giaccone G; Gilboa E; Gnjatic S; Hoos A; Hosmalin A; Jäger D; Kalinski P; Kärre K; Kepp O; Kiessling R; Kirkwood JM; Klein E; Knuth A; Lewis CE; Liblau R; Lotze MT; Lugli E; Mach JP; Mattei F; Mavilio D; Melero I; Melief CJ; Mittendorf EA; Moretta L; Odunsi A; Okada H; Palucka AK; Peter ME; Pienta KJ; Porgador A; Prendergast GC; Rabinovich GA; Restifo NP; Rizvi N; Sautès-Fridman C; Schreiber H; Seliger B; Shiku H; Silva-Santos B; Smyth MJ; Speiser DE; Spisek R; Srivastava PK; Talmadge JE; Tartour E; Van Der Burg SH; Van Den Eynde BJ; Vile R; Wagner H; Weber JS; Whiteside TL; Wolchok JD; Zitvogel L; Zou W; Kroemer G
Oncotarget; 2014 Dec; 5(24):12472-508. PubMed ID: 25537519
[TBL] [Abstract][Full Text] [Related]
14. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Kostova Y; Mantwill K; Holm PS; Anton M
Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapies for Cancer: Strategies, Challenges and Successes.
Das SK; Menezes ME; Bhatia S; Wang XY; Emdad L; Sarkar D; Fisher PB
J Cell Physiol; 2015 Feb; 230(2):259-71. PubMed ID: 25196387
[TBL] [Abstract][Full Text] [Related]
16. Trial Watch:: Oncolytic viruses for cancer therapy.
Pol J; Bloy N; Obrist F; Eggermont A; Galon J; Cremer I; Erbs P; Limacher JM; Preville X; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e28694. PubMed ID: 25097804
[TBL] [Abstract][Full Text] [Related]
17. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
Dong W; van Ginkel JW; Au KY; Alemany R; Meulenberg JJ; van Beusechem VW
Hum Gene Ther; 2014 Oct; 25(10):897-904. PubMed ID: 25093639
[TBL] [Abstract][Full Text] [Related]
18. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
Granot T; Yamanashi Y; Meruelo D
Mol Ther; 2014 Jan; 22(1):112-22. PubMed ID: 24025748
[TBL] [Abstract][Full Text] [Related]
19. Trial watch: Oncolytic viruses for cancer therapy.
Vacchelli E; Eggermont A; Sautès-Fridman C; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Jun; 2(6):e24612. PubMed ID: 23894720
[TBL] [Abstract][Full Text] [Related]
20. Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.
Das SK; Sarkar S; Dash R; Dent P; Wang XY; Sarkar D; Fisher PB
Adv Cancer Res; 2012; 115():1-38. PubMed ID: 23021240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
